The price of Inari Medical Inc (NASDAQ: NARI) closed at $43.23 in the last session, down -6.39% from day before closing price of $46.18. In other words, the price has decreased by -$2.95 from its previous closing price. On the day, 2514238 shares were traded.
Ratios:
We take a closer look at NARI’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 80.26. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 3.09. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on February 29, 2024, Downgraded its rating to Neutral and sets its target price to $55 from $85 previously.
On January 23, 2024, Needham started tracking the stock assigning a Buy rating and target price of $72.
On July 19, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $79.Robert W. Baird initiated its Outperform rating on July 19, 2023, with a $79 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 18 ’24 when Hoffman William sold 40,000 shares for $41.13 per share. The transaction valued at 1,645,079 led to the insider holds 1,003,296 shares of the business.
Hill, Mitch C. sold 6,000 shares of NARI for $251,461 on Mar 12 ’24. The Chief Financial Officer now owns 183,361 shares after completing the transaction at $41.91 per share. On Dec 15 ’23, another insider, Hoffman William, who serves as the Director of the company, sold 25,000 shares for $65.08 each. As a result, the insider received 1,627,073 and left with 1,045,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NARI now has a Market Capitalization of 2.68B and an Enterprise Value of 2.59B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.08 while its Price-to-Book (P/B) ratio in mrq is 5.37. Its current Enterprise Value per Revenue stands at 5.25 whereas that against EBITDA is 170.86.
Stock Price History:
The Beta on a monthly basis for NARI is 0.85, which has changed by -33.57% over the last 52 weeks, in comparison to a change of 26.95% over the same period for the S&P500. Over the past 52 weeks, NARI has reached a high of $71.85, while it has fallen to a 52-week low of $39.90. The 50-Day Moving Average of the stock is 50.80, while the 200-Day Moving Average is calculated to be 58.73.
Shares Statistics:
According to the various share statistics, NARI traded on average about 1.17M shares per day over the past 3-months and 2.52M shares per day over the past 10 days. A total of 57.76M shares are outstanding, with a floating share count of 49.52M. Insiders hold about 14.57% of the company’s shares, while institutions hold 85.39% stake in the company. Shares short for NARI as of Mar 15, 2024 were 3.58M with a Short Ratio of 3.07, compared to 4.97M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.18% and a Short% of Float of 7.84%.
Earnings Estimates
The company has 8 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.39, while EPS last year was -$0.04. The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.05 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$0.12 and -$0.95 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is $0.2, with 10 analysts recommending between $0.85 and -$0.11.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $138.37M. It ranges from a high estimate of $143.3M to a low estimate of $137.06M. As of the current estimate, Inari Medical Inc’s year-ago sales were $116.17M, an estimated increase of 19.10% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $141.16M, an increase of 21.00% over than the figure of $19.10% in the same quarter last year. There is a high estimate of $146.6M for the next quarter, whereas the lowest estimate is $138.43M.
A total of 11 analysts have provided revenue estimates for NARI’s current fiscal year. The highest revenue estimate was $592.3M, while the lowest revenue estimate was $584.91M, resulting in an average revenue estimate of $588.25M. In the same quarter a year ago, actual revenue was $493.63M, up 19.20% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $694.09M in the next fiscal year. The high estimate is $709M and the low estimate is $683.53M. The average revenue growth estimate for next year is up 18.00% from the average revenue estimate for this year.
